Abstract
Fluorescent antagonists offer the ability to interrogate G protein-coupled receptor pharmacology. With resonance energy transfer techniques, fluorescent antagonists can be implemented to monitor receptor–ligand interactions using assays originally designed for radiolabeled probes. The fluorescent nature of these antagonists also enables the localization and distribution of the receptors to be visualized in living cells. Here, we describe the generation of modified purinergic receptors with the NanoLuc luciferase or SNAP-tag, using the P1 adenosine A3 receptor as an example. We also describe the procedure of characterizing a novel fluorescent purinergic antagonist using ligand-mediated bioluminescence resonance energy transfer assays and confocal microscopy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbracchio MP, Burnstock G, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology. LVIII: Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341
Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63:641–683
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors, an update. Pharmacol Rev 63:1–34
Burnstock G (2017) Purinergic signalling: therapeutic developments. Front Pharmacol 8:661
Sarafoff N, Byrne RA, Sibbing D (2012) Clinical use of clopidogrel. Curr Pharm Des 18:5224–5239
Lau OC, Samarawickrama C, Skalicky SE (2014) P2Y2 receptor agonists for the treatment of dry eye disease: a review. Clin Ophthalmol 8:327–334
Garland SL (2013) Are GPCRs still a source of new targets? J Biomol Screen 18:947–966
Stoddart LA, Kilpatrick LE, Briddon SJ, Hill SJ (2015) Probing the pharmacology of G protein-coupled receptors with fluorescent ligands. Neuropharmacology 98:48–57
Stoddart LA, Vernall AJ, Denman JL, Briddon SJ, Kellam B, Hill SJ (2012) Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. Chem Biol 19:1105–1115
Arruda MA, Stoddart LA, Gherbi K, Briddon SJ, Kellam B, Hill SJ (2017) A non-imaging high throughput approach to chemical library screening at the unmodified adenosine-A3 receptor in living cells. Front Pharmacol 8:908
Vernall AJ, Stoddart LA, Briddon SJ, Ng HW, Laughton CA, Doughty SW, Hill SJ, Kellam B (2013) Conversion of a non-selective adenosine receptor antagonist into A3-selective high affinity fluorescent probes using peptide-based linkers. Org Biomol Chem 11:5673–5682
Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KD (2016) Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. Br J Pharmacol 173:3028–3037
Stoddart LA, Johnstone EK, Wheal AJ, Goulding J, Robers MB, Machleidt T, Wood KV, Hill SJ, Pfleger KD (2015) Application of BRET to monitor ligand binding to GPCRs. Nat Methods 12:661–663
Stoddart LA, Kilpatrick LE, Hill SJ (2018) NanoBRET approaches to study ligand binding to GPCRs and RTKs. Trends Pharmacol Sci 39:136–147
Soave M, Stoddart LA, Brown A, Woolard J, Hill SJ (2016) Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human beta1-adrenoceptor expressed in HEK-293 cells. Pharmacol Res 4:e00250
Christiansen E, Hudson BD, Hansen AH, Milligan G, Ulven T (2016) Development and characterization of a potent free fatty acid receptor 1 (FFA1) fluorescent tracer. J Med Chem 59:4849–4858
Rose RH, Briddon SJ, Hill SJ (2012) A novel fluorescent histamine H(1) receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands. Br J Pharmacol 165:1789–1800
Stoddart LA, Vernall AJ, Bouzo-Lorenzo M, Bosma R, Kooistra AJ, de Graaf C, Vischer HF, Leurs R, Briddon SJ, Kellam B, Hill SJ (2018) Development of novel fluorescent histamine H1-receptor antagonists to study ligand-binding kinetics in living cells. Sci Rep 8:1572
Conroy S, Kindon ND, Glenn J, Stoddart LA, Lewis RJ, Hill SJ, Kellam B, Stocks MJ (2018) Synthesis and evaluation of the first fluorescent antagonists of the human P2Y2 receptor based on AR-C118925. J Med Chem 61:3089–3113
Vernall AJ, Stoddart LA, Briddon SJ, Hill SJ, Kellam B (2012) Highly potent and selective fluorescent antagonists of the human adenosine A3 receptor based on the 1,2,4-triazolo(4,3-a)quinoxalin-1-one scaffold. J Med Chem 55:1771–1782
Dong C, Filipeanu CM, Duvernay MT, Wu G (2007) Regulation of G protein-coupled receptor export trafficking. Biochim Biophys Acta 1768:853–870
Keppler A, Pick H, Arrivoli C, Vogel H, Johnsson K (2004) Labeling of fusion proteins with synthetic fluorophores in live cells. Proc Natl Acad Sci U S A 101:9955–9959
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Soave, M., Goulding, J., Markus, R., Hill, S.J., Stoddart, L.A. (2020). Application of Fluorescent Purinoceptor Antagonists for Bioluminescence Resonance Energy Transfer Assays and Fluorescent Microscopy. In: Pelegrín, P. (eds) Purinergic Signaling. Methods in Molecular Biology, vol 2041. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9717-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9717-6_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9716-9
Online ISBN: 978-1-4939-9717-6
eBook Packages: Springer Protocols